/PRNewswire/ Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter.
NEW YORK, Aug. 10, 2023 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. . Such investors are advised to contact Robert S. Willoughby. -Today at 02:13 pm- MarketScreener
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Such.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Such.
/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Such.